Altogether, the actions of SGLT2 inhibitors in the prevention of renal Mg wasting and the subsequent amelioration of hypomagnesemia should be particularly beneficial in patients with CKD, given the relationship between serum Mg levels and the lower risk of all-cause mortality, which has been extensively observed. The gene discussed is SLC5A2; the disease is chronic kidney disease.